The analysis, that included data from 17,000 patients with the most common type of ovarian cancer, also confirmed the association of 18 of the previously published variants.
According to Cancer Research UK, there were 7,378 new cases of ovarian cancer in the UK in 2014. Around nine out of ten of these cases was epithelial ovarian cancer. The peak rate of cases is among women aged 75-79 years old.
"We know that a woman's genetic make-up accounts for about one third of her risk of developing ovarian cancer. This is the inherited component of disease risk," said Paul Pharoah from the University of Cambridge in the UK.
Inherited faults in genes such as BRCA1 and BRCA2 account for about 40 per cent of the inherited component.
These faults are rare (carried by about one in 300 people) and are associated with high lifetime risks of ovarian cancer - about 50 per cent for BRCA1 and 16 per cent for BRCA2 on average - as well as a high risk of breast cancer.
Previously, researchers had identified 27 common variants across the genome associated with ovarian cancer risk. However, some of these are associated only with rare subtypes of ovarian cancer.
The magnitude of the associated risk however is modest: together, the variants account for only about 4 per cent of the inherited component of disease.
The new study analysed the genomes of over 25,000 people with epithelial ovarian cancer and compared them to almost 41,000 healthy controls.
This enabled them to identify a further 12 variants associated with risk and confirm the association of 18 of the previously published variants; some of the other variants failed to replicate.
There are now known to be 30 risk variants, accounting for 6.5 per cent of the inherited component of risk.
"Ovarian cancer is clearly a very complex disease - even the 30 risk variants that we now know increase risk of developing the disease account for just a small fraction of the inherited component," said Catherine Phelan from the Moffitt Cancer Centre in the US.
The research appears in the journal Nature Genetics.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
